November 16, 2016 - By Darrin Black · 0 Comments
Nov 16 is a negative day so far for First Trust NYSE Arca Biotech ETF (NYSEARCA:FBT) as the ETF is active during the day after losing 0.41% to hit $101.35 per share. The exchange traded fund has 893.14 million net assets and 2.26% volatility this month.
Over the course of the day 4,906 shares traded hands, as compared to an average volume of 70,600 over the last 30 days for First Trust NYSE Arca Biotech ETF (NYSEARCA:FBT).
The ETF is -13.16% of its 52-Week High and 31.11% of its low, and is currently having ATR of 2.64. This year’s performance is -11.71% while this quarter’s performance is -0.43%.
The ETF’s YTD performance is -23.11%, the 1 year is -16.7% and the 3 year is 10.64%.
The ETF’s average P/E ratio is 20.78, the price to book is 3.9, the price to sales is 5.53 and the price to cashflow is 12.38. It was started on 6/23/2006. The fund’s top holdings are: Alexion Pharmaceuticals Inc. for 3.76% of assets, United Therapeutics Corporation for 3.73%, Celgene Corporation for 3.58%, Seattle Genetics Inc. for 3.52%, CEPHEID for 3.47%, Myriad Genetics Inc. for 3.46%, Gilead Sciences Inc. for 3.43%, Bio-Techne Corp for 3.43%, Incyte Corporation for 3.43%, Intrexon Corporation Common Sto for 3.39%. The ETF sector weights are: Healthcare 100.00%. The ETF currently as yield.
More important recent First Trust NYSE Arca Biotchnlgy Indx Fd (NYSEARCA:FBT) news were published by: Etfdailynews.com which released: “The Top Biotech ETF To Buy Right Now [First Trust NYSE Arca Biotchnlgy Indx Fd …” on June 15, 2015, also Etfdailynews.com published article titled: “The Best ETFs To Own In 2015 [PureFunds ISE Cyber Security ETF, First Trust …”, Benzinga.com published: “Once Beloved Momentum ETF Loses Its Momo” on October 27, 2016. More interesting news about First Trust NYSE Arca Biotchnlgy Indx Fd (NYSEARCA:FBT) was released by: Benzinga.com and their article: “Focus 5 ETF Gets A Dynamic Counterpart” with publication date: March 21, 2016.
First Trust NYSE Arca Biotechnology Index Fund , formerly First Trust Amex Biotechnology Index Fund, seeks investment results that correspond generally to the price and yield of an equity index called the NYSE Arca Biotechnology Index (the Index) (formerly the Amex Biotechnology Index). The company has a market cap of $893.14 million. The Fund will normally invest at least 90% of its assets in common stocks that comprise the Index. It currently has negative earnings. The Index is an equal dollar-weighted index designed to measure the performance of a cross section of companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Darrin Black